Document is current

Article History

Received: 17 September 2025

Accepted: 28 January 2026

First Online: 7 February 2026

Declarations

:

: This study was conducted as part of a quality assurance project and, in accordance with Danish law, was exempt from approval by the regional research ethics committee/institutional review board at central region Denmark (according to Danish law: LBK nr 1011 of 17/06/2023 § 42 d). The project underwent review and received approval from the Hospital Administration at Aarhus University Hospital as well as the Legal Department of the Central Denmark Region.This retrospective, register-based quality assurance study involved no direct patient contact or interventions. The study adhered to the principles of the Declaration of Helsinki.Since the study is performed as part of a quality assurance project, it is exempt from ethical approval and informed consent.

: Not applicable.

: RAB received lecture fees from Bayer, Pfizer and Novo Nordisk, unrelated to the submitted work, and is supported by a research grant from Novo Nordisk Foundation (NNF24OC0094646) and Lundbeck foundation (R467-2024-633) unrelated to the submitted work.CZS is supported by a research grant from Novo Nordisk Foundation (NNF17OC0029520) and Health Research Foundation of Central Denmark Region.Author DD, MFG, LBN, ABI, ML, TD, KDH report no conflict of interest.